Transthyretin amyloidoses: New strategies for therapeutic intervention

Drugs of the Future

Volumn 35, Issue 4, 2010, Pages 325-332

  Suhr, Ole B ^a   Lundgren, E ^b   Westermark, P ^c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; AMYLOID; APTAMER; DIFLUNISAL; DOXYCYCLINE; EPRODISATE; METHIONINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11 1F4; PREALBUMIN; PROTEIN INHIBITOR; RO 63 8695; SERUM AMYLOID P; SMALL INTERFERING RNA; STABILIZING AGENT; TAFAMIDIS MEGLUMINE; TETRAMER; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VALINE;

AGING; AMYLOIDOSIS; COMBINATORIAL CHEMISTRY; DRUG MECHANISM; DRUG STRUCTURE; GENE MUTATION; HEART DISEASE; HISTOPATHOLOGY; HUMAN; LIVER TRANSPLANTATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN FOLDING; REVIEW; TRANSTHYRETIN AMYLOIDOSIS;

EID: 77954612014     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.04.1452076     Document Type: Review

References (83)

1. Hammarstrom, P., Jiang, X., Hurshman, A.R., Powers, E.T., Kelly, J.W. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A 2002, 99(Suppl. 4): 16427-32.
2. McCutchen, S.L., Lai, Z., Miroy, G.J., Kelly, J.W., Colon, W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995, 34(41): 13527-36.
3. Pepys, M.B., Rademacher, T.W., Amatayakul-Chantler, S. et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A 1994, 91(12): 5602-6.
4. Hamazaki, H. Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's beta-amyloid peptide. J Biol Chem 1995, 270(18): 10392-4.
5. Janciauskiene, S., Garcia de Frutos, P., Carlemalm, E., Dahlback, B., Eriksson, S. Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem 1995, 270(44): 26041-4.
6. Webster, S., Rogers, J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J Neurosci Res 1996, 46(1): 58-66.
7. Murakami, T., Yi, S., Maeda, S. et al. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Am J Pathol 1992, 141(2): 451-6.
8. Botto, M., Hawkins, P.N., Bickerstaff, M.C. et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997, 3(8): 855-9.
9. Pepys, M.B., Herbert, J., Hutchinson, W.L. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417(6886): 254-9.
10. Snow, A.D., Willmer, J., Kisilevsky, R. Sulfated glycosaminoglycans: A common constituent of all amyloids? Lab Invest 1987, 56(1): 120-3.
11. Leveugle, B., Scanameo, A., Ding, W., Fillit, H. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: Inhibition by potentially therapeutic polysulfated compounds. Neuroreport 1994, 5(11): 1389-92.
12. Li, J.P., Galvis, M.L., Gong, F. et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 2005, 102(18): 6473-7.
13. Yan, S.D., Chen, X., Fu, J. et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382(6593): 685-91.
14. Yan, S.D., Zhu, H., Zhu, A. et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000, 6(6): 643-51.
15. Sousa, M.M., Du Yan, S., Fernandes, R., Guimaraes, A., Stern, D., Saraiva, M.J. Familial amyloid polyneuropathy: Receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001, 21(19): 7576-86.
16. Sousa, M.M., Yan, S.D., Stern, D., Saraiva, M.J. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 2000, 80(7): 1101-10.
17. Matsunaga, N., Anan, I., Forsgren, S. et al. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathol 2002, 104(5): 441-7.
18. Nyhlin, N., Ando, Y., Nagai, R. et al. Advanced glycation end product in familial amyloidotic polyneuropathy (FAP). J Intern Med 2000, 247(4): 485-92.
19. Ando, Y., Nyhlin, N., Suhr, O. et al. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Comm 1997, 232(2): 497-502.
20. Olsson, M., Hellman, U., Plante-Bordeneuve, V., Jonasson, J., Lang, K., Suhr, O.B. Mitochondrial haplogroup is associated with the phenotype of familial amyloidosis with polyneuropathy in Swedish and French patients. Clin Genet 2009, 75(2): 163-8.
21. Suhr, O.B., Herlenius, G., Friman, S., Ericzon, B.G. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 2000, 6(3): 263-76.
22. Stangou, A.J., Hawkins, P.N., Heaton, N.D. et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: Implications for amyloid fibrillogenesis. Transplantation 1998, 66(2): 229-33.
23. Nakamura, M., Ando, Y., Nagahara, S. et al. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther 2004, 11(10): 838-46.
24. Propsting, M.J., Blaschke, M., Haas, R.E., Genschel, J., Hedrich, H.J., Manns, M.P., Schmidt, H.H. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem Biophys Res Comm 1999, 260(2): 313-7.
25. Westermark, P., Sletten, K., Johansson, B., Cornwell, G.Gd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990, 87(7): 2843-5.
26. Bergstrom, J., Gustavsson, A., Hellman, U. et al. Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005, 206(2): 224-32.
27. Ihse, E., Ybo, A., Suhr, O.B., Lindqvist, P., Backman, C., Westermark, P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008, 216(2): 253-61.
28. Ranlov, P. The adoptive transfer of experimental mouse amyloidosis by intravenous injections of spleen cell extracts from casein-treated syngeneic donor mice. Acta Pathol Microbiol Scand 1967, 70(3): 321-35.
29. Johan, K., Westermark, G., Engstrom, U., Gustavsson, A., Hultman, P., Westermark P. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA 1998, 95(5): 2558-63.
30. Lundmark, K., Westermark, G.T., Olsen, A., Westermark, P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proc Natl Acad Sci U S A 2005, 102(17): 6098-102.
31. Mambule, C., Ando, Y., Anan, I. et al. Enhancement of AA-amyloid formation in mice by transthyretin amyloid fragments and polyethylene glycol. Biochim Biophys Acta 2000, 1474(3): 331-6.
32. Yazaki, M., Mitsuhashi, S., Tokuda, T. et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007, 7(1): 235-42.
33. Stangou, A.J., Heaton, N.D., Hawkins, P.N. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005, 352(22): 2356.
34. Connors, L.H., Lim, A., Prokaeva, T., Roskens, V.A., Costello, C.E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10(3): 160-84.
35. Lachmann, H.J., Booth, D.R., Booth, S.E. et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002, 346(23): 1786-91.
36. Solomon, A., Murphy, C., Westermark, P. Misclassification of amyloidosis is unwarranted. Blood 2006, 107(9): 3489-91.
37. Holmgren, G., Costa, P.M., Andersson, C. et al. Geographical distribution of TTR met30 carriers in northern Sweden: Discrepancy between carrier frequency and prevalence rate. J Med Genet 1994, 31(5): 351-4.
38. Buxbaum, J.N. Animal models of human amyloidoses: Are transgenic mice worth the time and trouble? FEBS Lett 2009, 583(16): 2663-73.
39. Yi, S., Takahashi, K., Naito, M. et al. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol 1991, 138(2): 403-12.
40. Santos, S.D., Fernandes, R., Saraiva, M.J. The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging 2010, 31(2): 280-9.
41. Sousa, M.M., Fernandes, R., Palha, J.A., Taboada, A., Vieira, P., Saraiva, M.J. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 2002, 161(5): 1935-48.
42. Buxbaum, J., Tagoe, C., Gallo, G., Reixach, N., French, D. The pathogenesis of transthyretin tissue deposition: Lessons from transgenic mice. Amyloid 2003, 10(Suppl. 1): 2-6.
43. Pokrzywa, M., Dacklin, I., Hultmark, D., Lundgren, E. Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. Eur J Neurosci 2007, 26(4): 913-24.
44. Miroy, G.J., Lai, Z., Lashuel, H.A., Peterson, S.A., Strang, C., Kelly, J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A 1996, 93(26): 15051-6.
45. Sekijima, Y., Dendle, M.A., Kelly, J.W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006, 13(4): 236-49.
46. Gales, L., Almeida, M.R., Arsequell, G., Valencia, G., Saraiva, M.J., Damas, A.M. Iodination of salicylic acid improves its binding to transthyretin. Biochim Biophys Acta 2008, 1784(3): 512-7.
47. Sato, T., Ando, Y., Susuki, S. et al. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 2006, 580(2): 491-6.
48. Kelly, J., Lansbury, P. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid 1994, 1: 186-205.
49. Lai, Z., Colon, W., Kelly, J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that con self-assemble into amyloid. Biochemistry 1996, 35(20): 6470-82.
50. Quintas, A., Vaz, D.C., Cardoso, I., Saraiva, M.J., Brito, R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001, 16: 16.
51. Zimmermann, T.S., Lee, A.C., Akinc, A. et al. RNAI-mediated gene silencing in non-human primates. Nature 2006, 441(7089): 111-4.
52. Benson, M.D., Kluve-Beckerman, B., Zeldenrust, S.R., Siesky, A.M., Bodenmiller, D.M., Showalter, A.D., Sloop, K.W. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006, 33(5): 609-18.
53. Sato, T., Susuki, S., Suico, M.A. et al. Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J 2007, 26(10): 2501-12.
54. Santos, S.D., Magalhaes, J., Saraiva, M.J. Activation of the heat shock response in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol 2008, 67(5): 449-55.
55. Wisniewski, T., Brown, D.R., Sigurdsson, E.M. Therapeutics in Alzheimer's and prion diseases. Biochem Soc Trans 2002, 30(4): 574-8.
56. Wisniewski, T., Sigurdsson, E.M. Therapeutic approaches for prion and Alzheimer's diseases. FEBS J 2007, 274(15): 3784-98.
57. Linke, R.P., Zucker-Franklin, D., Franklin, E.D. Morphologic, chemical, and immunologic studies of amyloid-like fibrils formed from Bence Jones proteins by proteolysis. J Immunol 1973, 111(1): 10-23.
58. Goldsteins, G., Persson, H., Andersson, K. et al. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc Natl Acad Sci U S A 1999, 96(6): 3108-13.
59. Terazaki, H., Ando, Y., Fernandes, R., Yamamura, K.I., Maeda, S., Saraiva, M.J. Immunization in familial amyloidotic polyneuropathy: Counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006, 86(1): 23-31.
60. Hrncic, R., Wall, J., Wolfenbarger, D.A., Murphy, C.L., Schell, M., Weiss, D.T., Solomon, A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000, 157(4): 1239-46.
61. Solomon, A., Weiss, D.T., Wall, J.S. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 2003, 18(6): 853-60.
62. Wall, J.S., Kennel, S.J., Paulus, M.J. et al. Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid 2005, 12: 149-56.
63. O'Nuallain, B., Wetzel, R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 2002, 99(3): 1485-90.
64. O'Nuallain, B., Hrncic, R., Wall, J.S., Weiss, D.T., Solomon, A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 2006, 176(11): 7071-8.
65. Lemere, C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res 2009, 175: 83-93.
66. Salloway, S., Sperting, R., Gilman, S. et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73(24): 2061-70.
67. Kayed, R., Head, E., Sarsoza, F. et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007, 2: 18.
68. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300(5618): 486-9.
69. Lord, A., Gumucio, A., Englund, H. et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis 2009, 36(3): 425-34.
70. Bunka, D.H.J., Stockley, P.G. Aptamers come of age - at last. Nat Rev Microbiol 2006, 4(8): 588-96.
71. Bunka, D.H., Mantle, B.J., Morten, I.J., Tennent, G.A., Radford, S.E., Stockley, P.G. Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J Biol Chem 2007, 282(47): 34500-9.
72. Ylera, F., Lurz, R., Erdmann, V.A., Fürste, J.P. Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem Biophys Res Commun 2002, 290(5): 1583-8.
73. Proske, D., Gilch, S., Wopfner, F., Schätzl, H.M., Winnacker, E.L., Famulok, M. Prion-protein-specific aptamer reduces PrPSc formation. ChemBioChem 2002, 3(8): 717-25.
74. Rahimi, F., Murakami, K., Summers, J.L., Chen, C.H., Bitan, G. RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS One 2009, 4(11): e7694.
75. Dember, L.M., Hawkins, P.N., Hazenberg, B.P. et al. Eprodisate for the treatment of renal disease in AA amyloidosis. New Engl J Med 2007, 356(23): 2349-60.
76. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W., Buxbaum, J.N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 2004, 101(9): 2817-22.
77. Suhr, O.B., Lang, K., Wikstrom, L. et al. Scavenger treatment of free radical injury in familial amyloidotic polyneuropathy: A study on Swedish transplanted and non-transplanted patients. Scand J Clin Lab Invest 2001, 61(1): 11-8.
78. Macedo, B., Batista, A.R., Ferreira, N., Almeida, M.R., Saraiva, M.J. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 2008, 1782(9): 517-22.
79. Palha, J.A., Ballinari, D., Amboldi, N. et al. 4′-iodo-4′- deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol 2000, 156(6): 1919-25.
80. Gertz, M.A., Lacy, M.Q., Dispenzieri, A. et al. A multicenter phase II trial of 4′-iodo-4′deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002, 9(1): 24-30.
81. Cardoso, I., Merlini, G., Saraiva, M.J. 4′-iodo-4′- deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: Screening for TTR fibril disrupters. FASEB J 2003, 17(8): 803-9.
82. Cardoso, I., Saraiva, M.J. Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB J 2006, 20(2): 234-9.
83. Okamoto, S., Wixner, J., Obayashi, K. et al. Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival. Liver Transpl 2009, 15(10): 1229-35.